ReviewMolecular carcinogenesis2026
Radiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements.
Review in Molecular carcinogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) has evolved significantly since its inception from treating benign conditions to becoming a cornerstone of cancer treatment. This review examines the complex interactions between RT and the immune system, highlighting its diverse effects on various immune cell populations, and exploring emerging strategies to enhance therapeutic outcomes. We discuss lessons learned from the re-emergence of low-dose irradiation for non-malignant disorders, the use of RT in managing graft-versus-host disease, and the importance of fractionation in modulating immune responses. This review addresses abscopal effects and their clinical implications. We emphasize the critical role of tumor-draining lymph nodes in mediating systemic immune responses. Recent advancements, including FLASH radiotherapy and targeted approaches to preserving immune function, have been explored. By integrating historical insights with contemporary research, this review aims to guide future RT practices and optimize their immunomodulatory potential, while minimizing adverse effects. We conclude by emphasizing the need for personalized approaches, biomarker identification, and innovative combination therapies to maximize the efficacy of RT in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.